Poly (ADP-Ribose) Polymerase Family, Member 9 (PARP9) (N-Term) Peptid
PARP9
Reaktivität: Human
Wirt: Synthetic
BP, WB
Produktnummer ABIN981372
Kurzübersicht für Poly (ADP-Ribose) Polymerase Family, Member 9 (PARP9) (N-Term) Peptid (ABIN981372)
Target
PARP9
(Poly (ADP-Ribose) Polymerase Family, Member 9 (PARP9))
Spezies
Human
Quelle
Synthetic
Applikation
Blocking Peptide (BP), Western Blotting (WB)
-
-
Protein Region
- N-Term
-
Produktmerkmale
- This is a synthetic peptide designed for use in combination with anti-PARP9 antibody (Catalog #: ARP33776_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Aufreinigung
- Purified
-
-
-
-
Applikationshinweise
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
-
-
Format
- Lyophilized
-
Rekonstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Konzentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Handhabung
- Avoid repeated freeze-thaw cycles.
-
Lagerung
- -20 °C
-
Informationen zur Lagerung
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- PARP9 (Poly (ADP-Ribose) Polymerase Family, Member 9 (PARP9))
-
Hintergrund
-
PARP9 contains 2 Macro domains and 1 PARP catalytic domain. PARP9 is overexpressed at significantly higher levels in fatal high-risk diffuse large B-cell lymphomas (DLB-CL) compared to cured low-risk tumors. Overexpression of PARP9 in B-cell lymphoma transfectants may promote malignant B-cell migration. The function of PARP9 remains unknown.
Alias Symbols: BAL, BAL1, DKFZp666B0810, DKFZp686M15238, FLJ26637, FLJ41418, MGC:7868
Protein Interaction Partner: DTX3L,DTX3L
Protein Size: 854 -
Molekulargewicht
- 96 kDa
-
Gen-ID
- 83666
-
NCBI Accession
- NM_031458, NP_113646
-
UniProt
- Q8IXQ6
Target
-
Sie sind hier:
